晚期肾细胞癌的研究进展。
Research progress on advanced renal cell carcinoma.
机构信息
Department of Urinary Surgery, Graduate School of Peking Union Medical College, Beijing Hospital, National Center of Gerontology, Beijing, China.
Department of Urinary Surgery, Xinle City Hospital, Shijiazhuang, Hebei Province, China.
出版信息
J Int Med Res. 2020 Jun;48(6):300060520924265. doi: 10.1177/0300060520924265.
Abstract
Renal cell carcinoma (RCC) is a malignant tumor and the third most common urinary disease. It was estimated that RCC affected over 350,000 individuals in 2013, and there are nearly 140,000 deaths annually due to this disease. The initial masses in RCC patients are mostly confined to a single organ. However, due to the metastatic spread of cancer cells through the circulatory system, more than 30% of RCC patients relapse after surgery. The appearance of distant metastases often means that patients enter the advanced stage of cancer with low quality of life and a short expected survival time. This review aims to describe the extant research on advanced RCC, including its pathophysiology, heterogeneity, diagnosis, treatment, and prospects. We try to highlight the most suitable means of treating advanced RCC patients, focusing on comprehensive personalized treatments.
摘要
肾细胞癌（RCC）是一种恶性肿瘤，是第三大常见的泌尿系统疾病。据估计，2013 年有超过 35 万名患者受到影响，每年有近 14 万人死于该病。RCC 患者的初始肿块大多局限于单个器官。然而，由于癌细胞通过循环系统转移，超过 30%的 RCC 患者在手术后复发。远处转移的出现通常意味着患者进入癌症晚期，生活质量低，预期生存时间短。本综述旨在描述晚期 RCC 的现有研究，包括其病理生理学、异质性、诊断、治疗和前景。我们试图强调治疗晚期 RCC 患者最合适的方法，重点是综合个性化治疗。
相似文献
1
Research progress on advanced renal cell carcinoma.晚期肾细胞癌的研究进展。
J Int Med Res. 2020 Jun;48(6):300060520924265. doi: 10.1177/0300060520924265.
2
The changing landscape of systemic therapy in metastatic renal cell carcinoma: an update.转移性肾细胞癌系统治疗的变化格局：更新。
Discov Med. 2020 May-Jun;29(158):191-199.
3
Mutations in renal cell carcinoma.肾细胞癌的突变。
Urol Oncol. 2020 Oct;38(10):763-773. doi: 10.1016/j.urolonc.2018.10.027. Epub 2018 Nov 23.
4
Transcriptomics in RCC.RCC 中的转录组学。
Urol Oncol. 2020 Oct;38(10):742-754. doi: 10.1016/j.urolonc.2019.12.003. Epub 2020 Mar 25.
5
Renal Cell Carcinoma: A Review.肾细胞癌：综述。
JAMA. 2024 Sep 24;332(12):1001-1010. doi: 10.1001/jama.2024.12848.
6
Tryptophan 2,3-dioxygenase in tumor cells is associated with resistance to immunotherapy in renal cell carcinoma.肿瘤细胞中的色氨酸 2,3-加双氧酶与肾细胞癌的免疫治疗抵抗有关。
Cancer Sci. 2021 Mar;112(3):1038-1047. doi: 10.1111/cas.14797. Epub 2021 Jan 25.
7
Updates to the Management of Kidney Cancer.肾癌的治疗进展。
J Natl Compr Canc Netw. 2018 May;16(5S):639-641. doi: 10.6004/jnccn.2018.0039.
8
Epidemiology, biology and treatment of sarcomatoid RCC: current state of the art.肉瘤样肾细胞癌的流行病学、生物学和治疗：当前的最新进展。
World J Urol. 2019 Jan;37(1):115-123. doi: 10.1007/s00345-018-2355-y. Epub 2018 Jun 1.
9
Renal cell carcinoma: current status and future prospects.肾细胞癌：现状与未来展望。
Cancer Treat Rev. 2005 Nov;31(7):536-45. doi: 10.1016/j.ctrv.2005.07.009. Epub 2005 Oct 17.
10
The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?晚期肾细胞癌围手术期治疗的未来：我们如何才能取得成功？
Future Oncol. 2019 May;15(15):1683-1695. doi: 10.2217/fon-2018-0951. Epub 2019 Apr 10.
引用本文的文献
1
Characterization of clear cell - Renal cell carcinoma using neutrophil - Lymphocyte ratio.利用中性粒细胞与淋巴细胞比值对透明细胞肾细胞癌进行特征分析。
Bioinformation. 2025 Mar 31;21(3):499-503. doi: 10.6026/973206300210499. eCollection 2025.
2
FBXW7/GSK3β-mediated proline-rich 11 degradation promotes oxidative DNA damage and inhibits tumor progression in renal cell carcinoma.FBXW7/GSK3β介导的富含脯氨酸蛋白11降解促进肾细胞癌中的氧化性DNA损伤并抑制肿瘤进展。
Theranostics. 2025 Feb 3;15(7):2814-2833. doi: 10.7150/thno.106018. eCollection 2025.
3
Comparing Sonazoid contrast-enhanced ultrasound to contrast-enhanced CT and MRI for differentially diagnosing renal lesions: a prospective multicenter study.对比声诺维超声造影与增强 CT、磁共振成像在鉴别诊断肾病变中的价值：一项前瞻性多中心研究。
World J Urol. 2024 May 8;42(1):302. doi: 10.1007/s00345-024-04885-7.
4
Bioinformatic Analysis and Clinical Case Studies Identify CD276 as a Promising Diagnostic Biomarker for Clear Cell Renal Cell Carcinoma.生物信息学分析和临床病例研究将 CD276 鉴定为透明细胞肾细胞癌有前途的诊断生物标志物。
Cancer Control. 2024 Jan-Dec;31:10732748241250181. doi: 10.1177/10732748241250181.
5
ExPert ConsEnsus on the management of Advanced clear-cell RenaL celL carcinoma: INDIAn Perspective (PEARL-INDIA).高级透明细胞肾细胞癌管理的专家共识：印度视角（PEARL-INDIA）。
BMC Cancer. 2023 Aug 9;23(1):737. doi: 10.1186/s12885-023-11237-y.
6
KLF9 inhibits the proliferation, invasion, and migration of renal cell carcinoma through the SDF-1/CXCR4 axis.KLF9 通过 SDF-1/CXCR4 轴抑制肾细胞癌的增殖、侵袭和迁移。
Kaohsiung J Med Sci. 2023 Jun;39(6):587-595. doi: 10.1002/kjm2.12671. Epub 2023 Apr 3.
7
Speckle-type POZ protein could play a potential inhibitory role in human renal cell carcinoma.斑点型 POZ 蛋白可能在人肾细胞癌中发挥潜在的抑制作用。
BMC Cancer. 2022 Dec 7;22(1):1277. doi: 10.1186/s12885-022-10340-w.
8
A Randomized Study on the Effect of Metformin Combined with Intensive-Exercise Diet Therapy on Glucose and Lipid Metabolism and Islet Function in Patients with Renal Cell Carcinoma and Diabetes.二甲双胍联合强化运动饮食疗法对肾癌合并糖尿病患者糖脂代谢及胰岛功能的随机研究
Dis Markers. 2022 Jul 15;2022:7383745. doi: 10.1155/2022/7383745. eCollection 2022.
9
Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study.在接受仑伐替尼联合帕博利珠单抗或依维莫司与舒尼替尼治疗的晚期肾细胞癌患者中与健康相关的生活质量结局（CLEAR）：一项随机、3 期研究。
Lancet Oncol. 2022 Jun;23(6):768-780. doi: 10.1016/S1470-2045(22)00212-1. Epub 2022 Apr 27.
本文引用的文献
1
Real-World Effectiveness and Tolerability of Pazopanib as First Targeted Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Chart Review in Latin America.帕唑帕尼作为转移性肾细胞癌一线靶向治疗的真实世界疗效和耐受性：拉丁美洲的回顾性图表分析。
Adv Ther. 2019 Dec;36(12):3446-3457. doi: 10.1007/s12325-019-01109-y. Epub 2019 Oct 19.
2
Paraneoplastic syndromes and oncological outcomes in renal cancer.肾癌中的副肿瘤综合征与肿瘤学结局
Niger J Clin Pract. 2019 Sep;22(9):1271-1275. doi: 10.4103/njcp.njcp_35_19.
3
Is there a role for stereotactic radiotherapy in the treatment of renal cell carcinoma?立体定向放射治疗在肾细胞癌治疗中是否有作用？
Clin Transl Radiat Oncol. 2019 Apr 26;18:104-112. doi: 10.1016/j.ctro.2019.04.012. eCollection 2019 Sep.
4
Cost-Effectiveness Analysis of Sunitinib versus Interferon-Alfa for First-Line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma in Singapore.新加坡舒尼替尼与干扰素-α一线治疗晚期和/或转移性肾细胞癌的成本-效果分析。
Int J Technol Assess Health Care. 2019 Jan;35(2):126-133. doi: 10.1017/S0266462319000059. Epub 2019 Mar 11.
5
The promising novel biomarkers and candidate small molecule drugs in kidney renal clear cell carcinoma: Evidence from bioinformatics analysis of high-throughput data.肾透明细胞癌中有前景的新型生物标志物和候选小分子药物：来自高通量数据生物信息学分析的证据
Mol Genet Genomic Med. 2019 May;7(5):e607. doi: 10.1002/mgg3.607. Epub 2019 Feb 21.
6
Cancer statistics, 2019.癌症统计数据，2019 年。
CA Cancer J Clin. 2019 Jan;69(1):7-34. doi: 10.3322/caac.21551. Epub 2019 Jan 8.
7
Perioperative Therapy in Renal Cell Carcinoma: What Do We Know, What Have We Learned, What's Next?肾细胞癌的围手术期治疗：我们知道什么，学到了什么，下一步是什么？
J Clin Oncol. 2018 Oct 29:JCO2018789131. doi: 10.1200/JCO.2018.78.9131.
8
Epidemiology of Renal Cell Carcinoma.肾细胞癌的流行病学。
Eur Urol. 2019 Jan;75(1):74-84. doi: 10.1016/j.eururo.2018.08.036. Epub 2018 Sep 19.
9
Role of radiotherapy in the treatment of renal cell cancer: updated and critical review.放射治疗在肾细胞癌治疗中的作用：最新综述与批判性评价
Tumori. 2017 Nov 23;103(6):504-510. doi: 10.5301/tj.5000640. Epub 2017 Jun 6.
10
Neutrophil-to-lymphocyte ratio as an independent predictor for survival in patients with localized clear cell renal cell carcinoma after radiofrequency ablation: a propensity score matching analysis.中性粒细胞与淋巴细胞比值作为局限性透明细胞肾细胞癌患者射频消融术后生存的独立预测指标：一项倾向评分匹配分析
Int Urol Nephrol. 2017 Jun;49(6):967-974. doi: 10.1007/s11255-017-1554-6. Epub 2017 Feb 28.
Zotero 插件